News

Evaluation of ex vivo drug combination optimization platform in recurrent high grade astrocytic glioma: An interventional, non-randomized, open-label trial protocol

Dr Toh Tan Boon’s team is excited to share their latest clinical trial protocol in PLOS ONE, “Evaluation of ex vivo drug combination optimization platform in recurrent high grade astrocytic glioma: An interventional, non-randomized, open-label trial protocol”.

Read More: Evaluation of ex vivo drug combination optimization platform in recurrent high grade astrocytic glioma: An interventional, non-randomized, open-label trial protocol – PLOS ONE

view MORE related

News

2024
医研所所长：运动再多饮食不节制 代谢难启动
More Details >
2024
Modified nano-sized cell particles boost cancer immunotherapy, reduce side effects
More Details >
2024
Breakthrough research extends hope for gastric cancer patients with peritoneal metastasis
More Details >
get in touch and

Contact Us

For inquiries pertaining to our R&D Programs, please contact Khew Si Ying at khewsiying@nus.edu.sg

The Institute for Digital Medicine (WisDM)

  • 28 Medical Drive, #05-COR,
    Singapore 117456

© National University of Singapore. All Rights Reserved.